1
|
Piérard GE, Piérard-Franchimont C, Szepetiuk G, Paquet P, Quatresooz P. The therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010; 10:1197-208. [PMID: 20560729 DOI: 10.1517/14712598.2010.500283] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
2
|
Raho G, Vena GA, Bizzoca A, Cassano N, Garofalo E, Congedo M, Gennarini G. Influence of infliximab on keratinocyte apoptosis in psoriasis patients. Immunopharmacol Immunotoxicol 2010; 33:227-31. [DOI: 10.3109/08923973.2010.487068] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
3
|
Vena G, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Guerra AP, Donato L, Cantoresi F, De Pità O, Pezza M, D'Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N. A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project. Int J Immunopathol Pharmacol 2009; 22:227-33. [DOI: 10.1177/039463200902200125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tumour necrosis factor-alpha, in the treatment of plaque psoriasis. In this open-label experience, 147 high-need patients suffering from plaque psoriasis, with a mean Psoriasis Area and Severity Index (PASI) of 18.8, and concomitant psoriatic arthritis (PsA) received subcutaneous injections of 40 mg of adalimumab every other week (EOW). This was actually the dosage regimen recommended for PsA, as the drug had not then been approved for psoriasis at the time of the patients' enrolment. At week 12, an improvement of at least 50% of the PASI (PASI-50) was observed in 111 (77%) patients. Continuation of treatment in responders with adalimumab 40 mg EOW led to a sustained response, with the PASI-50 achieved by 97% of patients in the as-treated analysis at week 24 (PASI-75 in 82% and PASI-90 in 45% out of 109 patients who received EOW injections up to week 24). Thirty subjects who failed to attain the PASI-50 response at week 12 were treated with adalimumab 40 mg every week for a further 12 weeks. At week 24, 80% of these patients obtained a PASI-50 response after dose escalation. Tolerability was good in the majority of patients. Only two patients discontinued treatment because of an adverse event (repeated flu-like episodes and a pleuropericarditis of unknown origin, respectively).
Collapse
Affiliation(s)
| | - A. Galluccio
- Unit of Dermatology, Ospedale Fatebenefratelli, Benevento
| | - C. De Simone
- Dermatology Clinic, University ‘Sacro Cuore’, Rome
| | | | | | - S. La Greca
- Dermatology Unit, Ospedale Garibaldi, Catania
| | - S. Dattola
- Dermatology Unit, Melito Porto Salvo (RC)
| | | | | | - F. Cantoresi
- Dermatology Clinic, University ‘La Sapienza’, Rome
| | - O. De Pità
- Istituto Dermopatico dell' lmmacolata; IRCCS, Rome
| | - M. Pezza
- Unit of Dermatology, Ospedale Fatebenefratelli, Benevento
| | | | - R. Vernaci
- Dermatology Unit, Melito Porto Salvo (RC)
| | - A. Miracapillo
- Dermatology Unit, Ospedale Miulli, IRCCS, Acquaviva delle Fonti (BA)
| | - G. Valenti
- Dermatology Unit, Ospedale Pugliese Ciaccio, Catanzaro, Italy
| | | |
Collapse
|
4
|
Altomare G, Ayala F, Berardesca E, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Guerra AP, Vena GA. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther 2008; 21 Suppl 2:S1-14. [DOI: 10.1111/j.1529-8019.2008.00226.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|